Business Wire

PHENOM

9.11.2022 14:01:48 CET | Business Wire | Press release

Share
Phenom Intelligent Talent Experience Platform Delivered 449% ROI According to 2022 Total Economic Impact Study

Phenom today announced that a composite organization using its Intelligence Talent Experience platform to hire, develop and retain talent achieved a 449% return on investment over three years with a payback period of less than six months — equaling more than $24M in cost savings and business benefits — according to a commissioned Total Economic Impact™ (TEI) Study conducted by Forrester Consulting on behalf of Phenom.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005200/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Phenom Intelligent Talent Experience platform delivered 449% ROI according to 2022 Total Economic Impact study (Graphic: Business Wire)

As labor and talent markets continue to waver, companies are looking for solutions to counteract the volatility with more efficient, automated hiring and retention processes, and an enhanced overall experience that differentiates them from competitors.

The TEI study uncovered that with Phenom, a composite organization representative of interviewed customers standardized and streamlined hiring and retention processes and achieved the following benefits by the third year:

  • 25% decrease in time to fill (or time to hire), with 30% of that decrease attributable to Phenom. Phenom facilitated faster hiring by accelerating efforts to identify, engage, screen, and schedule interviews with candidates, and enabling the growth of more qualified candidate pools.
  • 30% increase in internal hires, with 70% of that increase attributable to Phenom. Phenom improved the organization's ability to fill open positions with quality internal candidates instead of hiring talent externally, decreasing costs of new-hire onboarding, training, and time to productivity.
  • 50% more efficient spending to attract talent, with 80% of that improvement attributable to Phenom. With Phenom, the organization gained insights enabling it to target spending on job boards and social media that surface high-quality candidates cost-effectively.
  • 11 recruiter hours saved per week. Phenom saved the organization’s recruiters time sourcing and nurturing candidate leads, communicating with candidates, scheduling candidate interviews, and analyzing where leads are in the hiring process and who ultimately gets hired.

“[Phenom’s] artificial intelligence-enabled capabilities are a key element of how Phenom helps stakeholders execute faster and better across the talent acquisition, development and retention journey,” the Forrester study states. It also notes, “Its AI-based functionality reduces the time to fill roles, increases internal mobility, drives more productive spending to attract talent, and enhances recruiter productivity. As a result, organizations that use Phenom [Intelligent Talent Experience] are better equipped to hire, develop and retain talent.”

Additional Findings From The Forrester Consulting Total Economic Impact™ Study

To construct the study, Forrester interviewed Phenom clients, identifying the challenges they experienced previously, and the benefits, costs, risks, and outcomes they witnessed while using the platform.

Prior to implementing Phenom, the companies faced the following recruitment, employee development and retention challenges:

  • Competition for talent.
  • External and internal expectations for the candidate experience.
  • Limited ability to build and benefit from a talent community.
  • Lack of tools to support internal mobility, development and employee retention.
  • Cost of vacancies.
  • Manual and inefficient TA processes.
  • Inadequate analytics around hiring processes, spending and outcomes.

The Forrester study determined Phenom’s platform not only assisted with these challenges, it had a direct impact on cost savings with a payback period of less than six months. Over three years, the composite organization experienced these benefits:

  • $16.9M saved by decreasing time to fill a position.
  • $6.7M saved by increasing internal mobility.
  • $3.7M saved from more efficient spending to attract talent.
  • $2.3M saved from improving recruiter productivity.

Additional benefits identified in the study:

  • Improved candidate experience that elevated an organization’s brand.
  • Increased satisfaction and retention of current employees.
  • Reduced spending on external recruiters.
  • Improved productivity around recruitment events.

What Customers Said About Phenom in the Forrester Study

“We wouldn’t be able to keep up with the competition without the functionality Phenom provides,” said a vice president of talent acquisition at an industrial equipment company. The interviewee also stated, “Now, we can make informed business decisions with data…so, Phenom’s analytics help us avoid unnecessary costs, build our budgets, and determine where to shift acquisition spending so we’re not wasting money.”

“Sourcing efforts that previously took two hours can be done in 30 minutes using the CRM, especially by using its AI,” revealed a director of talent acquisition strategy and operations at a healthcare organization.

“We now have 1.5 million people in our talent pool, which helps us a lot, especially with Phenom’s AI-driven skills and job matching,” reported a global HR systems manager at a logistics company.

“Phenom has absolutely changed where and on what we spend money, and when to attract talent,” said a senior director of talent acquisition for a transportation company.

Intelligent Talent Experience is Transformational

More than 500 global and diverse companies are already using the Phenom Intelligent Talent Experience platform to connect people, data and interactions to deliver phenomenal moments with maximum efficiency throughout the talent journey.

With Phenom:

  • Candidates find and choose the right job faster.
  • Employees develop their skills and evolve.
  • Recruiters become wildly productive.
  • Managers build stronger-performing teams.
  • HR aligns employee development with company goals.
  • HRIS easily integrates existing HR tech to create a holistic infrastructure.

“Hiring and retention is now the most critical conversation in the boardroom,” said Mahe Bayireddi, CEO and co-founder of Phenom. “As the margins of companies tighten, company leaders are turning to HR to identify considerable cost savings through more efficient ways to hire, develop and retain quality talent. Consolidating spend with a solution that cuts across the most critical areas of both talent acquisition and management is possible — but only by combining and delivering on three core elements: experience, intelligence and automation.”

To see the full TEI study, or to learn more about Phenom, visit: info.phenom.com/forrester-tei

About Phenom

Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.

Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), Business Intelligence Group's Artificial Intelligence Excellence Awards (2021 & 2022), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005200/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release

Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye